Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisegliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.54 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisegliptin SCHEMBL164320 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2047576 | 0.99 | DPP4 (0.62) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2046787 | 0.99 | DPP4 (0.62) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2046833 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2049664 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2044893 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2051793 | 0.96 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2043885 | 0.96 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2048333 | 0.96 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2049221 | 0.95 | DPP4 (0.58) | DPP4DPP8DPP9PREPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | claimed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | claimed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| WO-2024015889-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-18 | — | — | WO | claimed |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2022-10-13 | — | — | US | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | claimed |
| JP-2011529945-A | — | — | 2011-12-15 | — | — | JP | claimed |
| EP-1712547-B1 | BICYCLOESTER DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2011-12-14 | — | — | EP | claimed |
| US-8053465-B2 | Bicycloester derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | claimed |
| US-20110263493-A1 | Treatment for diabetes in patients inappropriate for metformin therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | claimed |
| EP-2326326-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-06-01 | — | — | EP | claimed |
| EP-2323650-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | claimed |
| US-20100093825-A1 | Bicycloester derivative | FUKUDA YASUMICHI | 2010-04-15 | — | — | US | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2010015664-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20100093825-A1 | Bicycloester derivative | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885DPP8 8/4885DPP9 15/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20110263493-A1 | Treatment for diabetes in patients inappropriate for metformin therapy | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885DPP8 12/4885DPP9 3/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.